Innovation and Biomarkers in Cancer Drug Development (IBCD 2015) is dedicated to multi-stakeholder approaches to cancer drug development with new cancer biomarkers, including:
- Quality assurance and control
- Biomarker validation
- Regulatory acceptance
- The limitations of genomic profiling
- Challenges associated with immunological
- Interpretation of next generation sequencing results
- New challenges for statistics and bioinformatics
- Functional and imaging biomarkers
- Molecular based clinical research platforms
- Regulatory aspects and areas of co-development of drug and assays and co-development of combinations of drugs and assays
Innovation and Biomarkers in Cancer Drug Development (IBCD 2015) brings together attendees from industry, regulators and academia.
